For the Quarter Ending June 2025
North America
• Melatonin Spot Price in North America rose firmly through Q2 with the Price Index closing at USD 92,500/MT FOB New York by late June 2025. This uptrend reflected strong domestic and export demand from wellness, pharmaceutical and nutraceutical segments.
• Why did the price change in July 2025? Melatonin prices in July 2025 moved slightly higher as downstream players rushed to restock amid tightening inventory levels and ongoing consumer focus on sleep health. This renewed buying activity coincided with persistent supply discipline which encouraged a modest price lift.
• The Melatonin Price Forecast for Q3 2025 suggests a cautiously bullish trend, supported by expected seasonal demand for wellness formulations and increased marketing campaigns around stress and sleep support supplements.
• The Melatonin Production Cost Trend in Q2 remained stable as U.S. facilities operated without disruption. Raw material availability and manufacturing continuity enabled reliable supply output throughout the quarter.
• Demand accelerated during May and June as downstream buyers absorbed earlier inventories; this marked a shift from cautious purchasing in April to active procurement by early June, underpinning upward price movements.
• In April, the Melatonin Spot Price reflected a stable operating condition and soft but consistent offtake from domestic buyers. By June, active restocking led to a notable gain across the quarter.
• The Melatonin Demand Outlook remained robust across the wellness and pharmaceutical verticals. Brands and distributors responded to rising consumer awareness with advanced procurement and product formulation.
• Exporters benefited from highly efficient U.S. logistics and no major shipping delays. Strong export fulfilment capabilities bolstered international confidence in American-origin Melatonin.
• Inventory drawdown accelerated in June as downstream formulators moved to secure Q3 supply in advance. This proactive strategy reflected heightened caution over potential future price surges.
• Despite the bullish sentiment, no production bottlenecks or material sourcing challenges were reported in Q2, ensuring a well-balanced supply-demand dynamic.
Asia Pacific
• The Melatonin Spot Price in Shanghai declined modestly across Q2, with the Price Index settling at USD 66,150/MT FOB Shanghai by late June. Seasonal consumption slowdown and high inventory levels pressured prices downward.
• Why did the price change in July 2025? Melatonin prices in China remained mostly unchanged in July 2025 as exporters held offers steady amidst persistent oversupply and passive demand. Sellers aimed to stabilize the market without deepening discounts, especially as input and logistics costs stayed consistent.
• The Melatonin Price Forecast for Q3 2025 remains cautiously bearish unless export momentum improves. Without significant stimulus or tender activity from overseas buyers, prices may remain rangebound.
• The Melatonin Production Cost Trend held steady during Q2 with uninterrupted manufacturing operations across China. Sufficient feedstock access and smooth processing cycles kept costs predictable.
• Limited price movement during April–June reflected subdued export interest and soft seasonal demand, especially as longer daylight hours reduced consumer reliance on supplemental melatonin.
• The small price dips seen in May and June were inventory-led, as manufacturers sought to offload excess stock from previous cycles to maintain competitiveness in the global market.
• The Melatonin Demand Outlook was subdued, particularly from overseas markets. While wellness and pharma sectors sustained baseline consumption, no large-scale procurement revived market strength.
• Export logistics remained fluid throughout the quarter. Port operations in Shanghai and other key terminals ensured consistent global dispatches, helping prevent price volatility.
• Domestic buyers practiced controlled procurement, avoiding speculative purchases. This sentiment, rooted in sufficient running stock and muted consumer pull, shaped a flat market environment.
• The absence of any significant procurement from Europe or North America in May–June further dampened overall market confidence, keeping pricing trends neutral to soft.
Europe
• The Melatonin Spot Price in Europe showed stability in Q2 2025, with the Price Index hovering around USD 79,500/MT CFR Hamburg, underpinned by steady demand from the health supplement, pharma, and OTC sleep aid markets.
• Why did the price change in July 2025? In July 2025, Melatonin prices in Europe edged slightly higher due to anticipatory restocking by distributors ahead of expected Q3 wellness product launches. Incremental improvement in consumer sentiment in Northern and Western Europe supported this uptick.
• The Melatonin Price Forecast for Q3 remains mildly positive, backed by seasonal demand for OTC sleep support and wellness-focused products as part of post-summer formulation cycles.
• The Melatonin Production Cost Trend remained stable in Q2 for imported material from China and the U.S., with no significant logistics surcharges or customs bottlenecks affecting CIF values.
• European buyers adopted a lean inventory strategy in April–May, avoiding excess stockholding amid subdued early-summer demand. However, June saw a shift toward pre-emptive purchasing to avoid potential Q3 spot escalations.
• The Melatonin Demand Outlook in Europe remained balanced. While food and nutraceutical segments showed consistent interest, industrial and veterinary sectors displayed a modest pullback.
• Port logistics in key EU hubs like Hamburg, Antwerp, and Rotterdam operated smoothly throughout the quarter, enabling timely inbound shipments and steady supply chain continuity.
• The April–May period witnessed relatively flat pricing as buyers focused on prior inventory utilization. New orders began to emerge only in late June, tightening the supply pipeline slightly.
• European wellness brands adjusted their sourcing rhythm to match summer consumer preferences. Melatonin’s appeal in natural sleep aids and mood-balancing products saw a marginal increase in market pull by the end of Q2.
• No major macroeconomic disruptions, freight rate hikes, or policy changes occurred that could significantly affect production or importation costs, keeping the region’s Melatonin market structurally sound.
For the Quarter Ending March 2025
North America
In the first quarter of 2025, the Melatonin market in North America recorded a quarterly price rise of around 1.55% from previous quarter. This increase was supported by active procurement from melatonin supplement manufacturers and distributors. The seasonal transition from winter to spring played a part in keeping demand firm as consumers remained focused on sleep support and general wellness. The pharmaceutical and nutraceutical sectors showed steady offtake, especially as buyers moved to maintain well-planned inventories ahead of warmer months.
Melatonin suppliers in the region also benefited from smooth logistics and favourable supply conditions. Some influence came from ongoing tariff structures that encouraged local purchasing activity and kept buying interest stable for most of the quarter. Melatonin distributors adjusted their procurement cycles smartly to secure stock while avoiding overbuild, which kept supply-demand balanced.
Overall, the North American Melatonin market displayed healthy activity in first quarter of 2025 which was backed by solid downstream demand, good inventory management and supportive seasonal factors. The market sentiment stayed positive with suppliers reporting regular inquiries and moderate price adjustments.
Asia Pacific
In Asia Pacific, the Melatonin market experienced a modest average price increase of 0.10% during the first quarter of 2025. This trend was largely shaped by steady procurement activities from melatonin supplement and nutraceutical producers in the region. The Lunar New Year holidays in February resulted in temporarily slowed operations. This market temporary production slowdown was balanced by post-holiday restocking and helped in supporting the prices in upward direction.
Seasonal transition from winter to spring also contributed to sustained demand from downstream sectors such as pharmaceuticals and personal care. Melatonin suppliers in key exporting countries maintained reliable inventory positions and helped to ensure smooth distribution within the region. Although some downstream buyers showed cautious purchasing early in the quarter, but the strategic procurement activity picked up gradually as the quarter concluded.
Melatonin distributors responded to market signals and managed inventories effectively to match demand trends. Overall, the market remained balanced without sharp price fluctuations. The slight increase reflected healthy downstream consumption, supportive procurement strategies, and a steady pace of logistical operations across the Asia Pacific Melatonin market during Q1 2025.
Europe
The European Melatonin market in the first quarter of 2025 maintained a steady and controlled pricing pattern and broadly reflected the global market movements. Although pricing levels displayed minor variations across sources, the overall market sentiment held cautiously firm. Price levels demonstrated general stability with a modest upward inclination. This was supported by consistent demand from the pharmaceutical and nutraceutical sectors where melatonin supplements continued to gain consumer interest for sleep health and general wellness.
Melatonin suppliers in Europe reported regular inquiries and maintained strategic procurement schedules to prevent supply tightness. Distributors displayed careful inventory planning which helped in keeping market activity well balanced. Seasonal transition from colder months to early spring influenced purchasing patterns with steady buying observed throughout. The mild rise in demand was mainly driven by preparation for upcoming production cycles and positive downstream sentiment. The overall European Melatonin market in first quarter of 2025 remained steady. The moderate activity from both buyers and suppliers was reflected in a balanced supply-demand fundamentals and smooth distribution conditions.
For the Quarter Ending December 2024
North America
During quarter 4 of 2024, Melatonin prices in North America, especially in the US demonstrated a price increase of around 3.2% across the quarter. Values rose from $82080 per MT in October to $84700 per MT FOB New York in December 2024, displaying positive momentum. Price trends were driven by consistent purchasing activity from pharmaceutical and nutraceutical sectors, coupled with regular new customer inquiries throughout Q4.
Port infrastructure improvements and better logistics further supported price appreciation across the US. Market participants maintained high TEU volumes, with December bringing additional momentum as domestic suppliers implemented strategic pricing before the Christmas holiday. Export prices strengthened in the US market given the high offtake.
The market followed robust seasonal trends as 2024 concluded. Sustained end-user demand continued throughout the quarter, especially in pharmaceutical applications. This combination created an environment where supply chain stabilization and rising demand drove prices higher.
APAC
In Q4 2024, Melatonin prices in the Chinese domestic market demonstrated a consistent downward trend, declining from $73850 per MT in October to $72950 per MT FOB Shanghai by December 2024. The quarter began with Chinese Golden Week in October, which temporarily paused market activities, though international buyers maintained supply chain stability through advance procurement despite the production halt.
The downward momentum continued into November despite some resistance from China's nutraceutical sector, particularly from Western market demand. While lower freight rates provided some cost relief to manufacturers through improved logistics efficiency, this wasn't enough to reverse the overall declining price trajectory.
December saw further price softening as manufacturers implemented destocking initiatives ahead of the holiday season. Although demand remained stable across domestic and international channels, the continued inventory optimization efforts by producers sustained the downward pressure on prices. This persistent decline throughout the quarter created favorable buying conditions, even as fundamental demand stayed resilient.
Europe
Germany's Melatonin market in Q4 2024 experienced several notable fluctuations influenced by supply-demand dynamics and strategic inventory management. The quarter commenced with an upward price trajectory, driven by intensifying demand patterns and ongoing logistics disruptions affecting timely deliveries. By early November, the market witnessed heightened pressure as end-user demand stayed high while supply remained constrained. This imbalance created favorable conditions for sellers, who capitalized by implementing strategic price increases and enjoying improved profit margins.
Mid-November saw further tightening of supply chains, particularly affecting European distribution networks. However, the market dynamics shifted significantly in December as major European distributors initiated systematic inventory reduction programs. This strategic move created opportunities for buyers, leading to increased sourcing from Asian manufacturers who offered competitive pre-holiday rates. Despite these procurement shifts, the underlying pharmaceutical sector consumption remained remarkably stable.
The quarter concluded with a moderation in prices, primarily attributed to strategic inventory management decisions rather than any fundamental weakening in demand patterns. Industrial consumers, particularly in the pharmaceutical sector, maintained steady consumption levels throughout the period. Asian suppliers gained market share during this period, capitalizing on European inventory reduction initiatives.
For the Quarter Ending September 2024
North America
The Melatonin market in North America showcased moderate stability during Q3 2024, with the United States retaining its status as the primary trading hub. Price levels followed a gradual downward trajectory, declining from $86000/MT to $81960/MT FOB New York from July to September 2024. This quarter's softening prices contrasted with the previous quarter's continued depreciation, as market gained momentum in the later in the quarter. The modest price depreciation reflected subtle shifts in industry dynamics amid steady broader economic indicators.
Despite the slight price erosion, consumption patterns from domestic nutraceutical and pharmaceutical industries remained dependable, while efficient logistics management helped maintain supply-side balance. The market demonstrated resilience amid persistent operational challenges, including maritime congestion, shipping costs, and distribution network intricacies. The gentle price decline was partially influenced by competitive pricing in China's market, a key Melatonin supplier, creating a ripple effect across the American nutraceutical sector.
The measured price depreciation, occurring gradually across the quarter, indicates evolving market fundamentals while maintaining underlying stability. This trend aligns with broader regional patterns, showcasing the North American Melatonin market's ability to adapt despite ongoing supply chain complexities. The delicate balance between regional demand, global supply dynamics, and logistical factors has fostered a nuanced yet stable pricing environment.
APAC
The Melatonin market in Asia-Pacific displayed a slight downward pricing trend in Q3 2024, characterized by measured market adjustments. China's market experienced modest price softening quarter-over-quarter, while maintaining its position as the regional price benchmark. The market witnessed a gentle decline in price levels, with export values easing from $77700/MT to $73025/MT FOB Shanghai between July and September 2024.
This controlled price depreciation reflected well-managed operational factors and steady market fundamentals. Demand patterns maintained consistent procurement from nutraceutical and pharmaceutical industries, both domestic and international, while supply elements remained abundant despite ongoing production costs and operational considerations. The interaction between production capacity and logistical frameworks facilitated a controlled market adjustment throughout the quarter.
Market stability, despite the price softening, was evident through steady buyer engagement and predictable order patterns. These consistent demand indicators, combined with efficient operational management including freight expenses and supply chain processes, allowed industry participants to maintain workable margins. China's domestic market continued to guide regional price trends, balancing international procurement patterns with domestic consumption dynamics. The coordination between production capabilities and logistical frameworks supported a controlled market adjustment.
Europe
The European Melatonin landscape experienced a gentle price decline mimicking the Asian markets during Q3 2024, with Germany's market dynamics serving as the key regional indicator. The quarterly performance showed consistent but slightly decreasing price levels between the first and second half, maintaining overall market balance. Despite historical volatility, the market demonstrated controlled adjustment with steady quarterly performance.
The measured price depreciation stemmed from well-managed supply capabilities and steady demand patterns amid high inventory levels. Manufacturing processes, particularly in Asian production centers, maintained optimal output levels influencing the gradual price adjustment in Germany. This was supported by reliable demand from pharmaceutical and nutraceutical sectors maintaining predictable procurement activities.
Germany's market trends continued to provide a benchmark for European pricing patterns, exhibiting consistent seasonal performance despite the modest price softening. Through operational challenges, the market maintained its fundamental equilibrium, underlining the European Melatonin market's inherent stability. The balance between supply capabilities, sectoral demand patterns, and regional market forces fostered a slightly declining but stable pricing environment, characterized by measured adjustment and market equilibrium across Europe.
FAQs
1. What is Melatonin used for?
Melatonin is a naturally occurring hormone widely used as a dietary supplement to support sleep regulation, circadian rhythm disorders, and jet lag management. It is also researched for its antioxidant properties and potential immune-modulating effects.
2. Which sectors drive the demand for Melatonin?
The demand is primarily driven by the nutraceutical and pharmaceutical sectors, especially in the production of over-the-counter sleep aids, wellness formulations, and stress-reducing supplements. Seasonal peaks are often observed due to changing daylight patterns and consumer health awareness.
3. What are the key factors influencing Melatonin prices?
Prices are impacted by synthesis costs of tryptophan-based intermediates, production capacity utilization in China and India, export regulations, and seasonal demand trends across North America and Europe. Contract manufacturing cycles and inventory strategies also contribute to price fluctuations.
4. Which countries are major exporters of Melatonin?
China and India are the leading exporters of Melatonin, supplying bulk APIs and finished formulations to major markets like the U.S., Germany, Italy, and other parts of Europe and Southeast Asia.
5. What are common forms of Melatonin available in the market?
Melatonin is commonly available as tablets, capsules, soft gels, and gummies. It is also incorporated into functional beverages and sleep-support blends, often combined with magnesium, chamomile, or valerian extracts for synergistic effect.
